NinaMED raised US$13.75M to license and commercialize EBT Medical's NiNA System, a noninvasive at-home neuromodulation therapy targeting the saphenous nerve for overactive bladder.
Key Takeaways
- NinaMED completed US$13.75 million in financing led by SPRIM Global Investments
- NinaMED holds an exclusive global license from EBT Medical for the NiNA System
- NiNA is a noninvasive